سعر امبروفيكا 140 مجم 90 كبسولة 2024

Imbruvica (ibrutinib) 140 mg oral capsules, pack of 90; a Bruton tyrosine kinase inhibitor for B-cell malignancies and chronic graft-versus-host disease.

• Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), including CLL/SLL with 17p deletionPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Waldenström’s macroglobulinemiaPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Chronic graft-versus-host disease after failure of one or more lines of systemic therapyPopulation: Adults and children aged 1 year and olderDailyMed (U.S. National Library of Medicine)

• Most common (>=30%) in B-cell malignancies: thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, bruising and nausea.International label, same product · DailyMed (U.S. National Library of Medicine)

• The US label lists no contraindications.International label, same product · DailyMed (U.S. National Library of Medicine)

• Hemorrhage, including fatal bleeding; concomitant anticoagulants or antiplatelet agents increase the risk of major hemorrhage.International label, same product · DailyMed (U.S. National Library of Medicine)
• Serious infections; monitor for fever and infections and treat promptly.International label, same product · DailyMed (U.S. National Library of Medicine)
• Cardiac arrhythmias, cardiac failure and sudden death, and hypertension can occur.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong or moderate CYP3A inhibitors (e.g. posaconazole, voriconazole); grapefruit and Seville orangesMay increase ibrutinib concentrations and toxicity; dose modification or avoidance per label; avoid grapefruit and Seville oranges.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A inducersMay decrease ibrutinib concentrations; avoid coadministration.DailyMed (U.S. National Library of Medicine)
• Anticoagulants and antiplatelet agentsIncrease the risk of major hemorrhage.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on animal studies (embryofetal toxicity including structural abnormalities); no human data.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; advise not to breastfeed during treatment and for 1 week after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Ibrutinib: Covalent inhibitor of Bruton tyrosine kinase, blocking B-cell receptor signalling in malignant B cells.